Telomir Pharmaceuticals Inc
TELO1.410USD
+0.040+2.92%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
47.70MMarket Cap
LossP/E TTM
More Details of Telomir Pharmaceuticals Inc Company
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.
Telomir Pharmaceuticals Inc Info
Ticker SymbolTELO
Company nameTelomir Pharmaceuticals Inc
IPO dateFeb 09, 2024
CEOAminov (Erez)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endFeb 09
Address900 West Platt Street, Suite 200
CityTAMPA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33606
Phone18138642562
Websitehttps://telomirpharma.com/
Ticker SymbolTELO
IPO dateFeb 09, 2024
CEOAminov (Erez)
Company Executives of Telomir Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.01M
+3288.20%
Mr. Matthew Pratt Whalen, CPA
Mr. Matthew Pratt Whalen, CPA
Independent Director
Independent Director
--
--
Mr. Alan Weichselbaum
Mr. Alan Weichselbaum
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Matthew Paul Del Giudice, M.D.
Dr. Matthew Paul Del Giudice, M.D.
Independent Director
Independent Director
--
--
Mr. Edward MacPherson
Mr. Edward MacPherson
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.01M
+3288.20%
Mr. Matthew Pratt Whalen, CPA
Mr. Matthew Pratt Whalen, CPA
Independent Director
Independent Director
--
--
Mr. Alan Weichselbaum
Mr. Alan Weichselbaum
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Matthew Paul Del Giudice, M.D.
Dr. Matthew Paul Del Giudice, M.D.
Independent Director
Independent Director
--
--
Mr. Edward MacPherson
Mr. Edward MacPherson
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Bay Shore Trust
19.58%
Mira Pharmaceuticals, Inc
10.24%
McNulty (Brian Patrick)
5.46%
DeJoria (John Paul)
5.16%
The Vanguard Group, Inc.
3.20%
Other
56.35%
Shareholders
Shareholders
Proportion
Bay Shore Trust
19.58%
Mira Pharmaceuticals, Inc
10.24%
McNulty (Brian Patrick)
5.46%
DeJoria (John Paul)
5.16%
The Vanguard Group, Inc.
3.20%
Other
56.35%
Shareholder Types
Shareholders
Proportion
Corporation
29.82%
Individual Investor
15.16%
Investment Advisor
4.96%
Investment Advisor/Hedge Fund
1.05%
Hedge Fund
0.68%
Research Firm
0.13%
Other
48.20%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
97
2.75M
8.52%
-985.35K
2025Q2
89
13.66M
45.90%
+660.23K
2025Q1
87
13.90M
46.70%
+955.11K
2024Q4
74
13.75M
46.22%
+2.38M
2024Q3
65
14.68M
49.58%
+3.19M
2024Q2
47
12.97M
43.79%
+1.79M
2024Q1
17
12.67M
42.78%
+1.58M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Bay Shore Trust
6.73M
20.85%
-89.00K
-1.30%
Dec 31, 2024
McNulty (Brian Patrick)
1.88M
5.82%
-49.00K
-2.54%
Dec 31, 2024
DeJoria (John Paul)
1.77M
5.5%
+1.77M
--
Sep 09, 2025
The Vanguard Group, Inc.
1.12M
3.46%
-139.96K
-11.12%
Jun 30, 2025
Aminov (Erez)
1.01M
3.13%
+979.88K
+3288.20%
Dec 31, 2024
Eagle (Craig)
487.81K
1.51%
--
--
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
357.01K
1.11%
-761.63K
-68.09%
Jun 30, 2025
Millennium Management LLC
247.70K
0.77%
+247.70K
--
Jun 30, 2025
Geode Capital Management, L.L.C.
196.88K
0.61%
-232.37K
-54.13%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
iShares Russell 2000 ETF
0%
Global X Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Telomir Pharmaceuticals Inc?
The top five shareholders of Telomir Pharmaceuticals Inc are:
Bay Shore Trust holds 6.73M shares, accounting for 20.85% of the total shares.
McNulty (Brian Patrick) holds 1.88M shares, accounting for 5.82% of the total shares.
DeJoria (John Paul) holds 1.77M shares, accounting for 5.50% of the total shares.
The Vanguard Group, Inc. holds 1.12M shares, accounting for 3.46% of the total shares.
Aminov (Erez) holds 1.01M shares, accounting for 3.13% of the total shares.
Bay Shore Trust holds 6.73M shares, accounting for 20.85% of the total shares.
McNulty (Brian Patrick) holds 1.88M shares, accounting for 5.82% of the total shares.
DeJoria (John Paul) holds 1.77M shares, accounting for 5.50% of the total shares.
The Vanguard Group, Inc. holds 1.12M shares, accounting for 3.46% of the total shares.
Aminov (Erez) holds 1.01M shares, accounting for 3.13% of the total shares.
What are the top three shareholder types of Telomir Pharmaceuticals Inc?
The top three shareholder types of Telomir Pharmaceuticals Inc are:
Bay Shore Trust
Mira Pharmaceuticals, Inc
McNulty (Brian Patrick)
Bay Shore Trust
Mira Pharmaceuticals, Inc
McNulty (Brian Patrick)
How many institutions hold shares of Telomir Pharmaceuticals Inc (TELO)?
As of 2025Q3, 97 institutions hold shares of Telomir Pharmaceuticals Inc, with a combined market value of approximately 2.75M, accounting for 8.52% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -37.38%.
What is the biggest source of revenue for Telomir Pharmaceuticals Inc?
In --, the -- business generated the highest revenue for Telomir Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
